Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion

Clicks: 409
ID: 119185
1996
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The synthetic peptides DP-107 and DP-178 (T-20), derived from separate domains within the human immunodeficiency virus type 1 (HIV-1) transmembrane (TM) protein, gp4l, are stable and potent inhibitors of HIV-1 infection and fusion. Using a computer searching strategy (computerized antiviral searchin …
Reference Key
dm1996proceedingspeptides Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lambert DM;Barney S;Lambert AL;Guthrie K;Medinas R;Davis DE;Bucy T;Erickson J;Merutka G;Petteway SR;;
Journal Proceedings of the National Academy of Sciences of the United States of America
Year 1996
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/8700906
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't amino acid sequence peptides / chemistry sequence alignment Comparative Study Molecular Sequence Data protein structure structure-activity relationship parainfluenza virus 3 secondary pmid:8700906 pmc39932 doi:10.1073/pnas.93.5.2186 d m lambert s barney s r petteway antiviral agents* circular dichroism measles virus / chemistry* membrane fusion* human / chemistry* respiratory syncytial viruses / chemistry* viral fusion proteins / chemistry*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.